Physician profile
Rikki Carter
NPI 1639993298
$2,061.26
in general payments reported to CMS, 2019-2025
18 companies · $1,987 in 2025
The $1,987 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $74.32 · 2025: $1,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,961.27 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $271.23 | 2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $248.45 | 2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $229.86 | 2024-2025 | Dupixent, Libtayo |
| Verona Pharma, INC. | $180.75 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $163.38 | 2025 | Tezspire, Breztri, Airsupra |
| Baxter Healthcare | $146.16 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $138.11 | 2025 | Glassia |
| Viatris Specialty LLC | $119.68 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $104.78 | 2025 | |
| Grifols USA, LLC | $102.38 | 2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $95.22 | 2024-2025 | Tyvaso, Tyvaso, Remodulin |
| Amgen INC. | $58.41 | 2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.12 | 2025 | Ofev |
| Glaxosmithkline, LLC. | $42.19 | 2025 | Nucala |
| Genzyme Corporation | $32.83 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $30.97 | 2025 | Arikayce |
| Abbvie INC. | $27.85 | 2025 | |
| Shionogi INC | $14.89 | 2025 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rikki Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.